BPC-157 for Women: Gut Healing, IC, and Why IBS Hits Us Harder
The most-researched healing peptide meets the population that needs it most. IBS is 2x more common in women. 80% of autoimmune patients are female. A pilot study showed remarkable results for interstitial cystitis. Here's what the science says.
BPC-157 is the most talked-about peptide in the regenerative space — and with over 180 preclinical publications documenting its effects on tissue repair, angiogenesis, and anti-inflammatory signaling, the attention is warranted. But most of the conversation around BPC-157 centers on athletes, bodybuilders, and men recovering from sports injuries.
That framing misses the bigger story. The conditions BPC-157 targets — gut permeability, inflammatory bowel conditions, tissue repair, immune modulation — disproportionately affect women. IBS is twice as common in women as men. Eighty percent of autoimmune patients are female. Interstitial cystitis, a chronic bladder condition causing pelvic pain and urinary urgency, affects women at rates 5–10 times higher than men.
And the most remarkable human data for BPC-157 so far? It comes from a study conducted entirely in women.
The Interstitial Cystitis Study
In 2024, researchers conducted a pilot study giving BPC-157 injections (10mg total) to 12 women aged 39–76 with moderate to severe interstitial cystitis that had not responded to conventional treatment. The results: 10 of the 12 women reported complete resolution of symptoms after a single treatment. The remaining two reported 80% improvement. No participants dropped out. No adverse events were reported.
This is a small, uncontrolled pilot study — not a Phase 3 RCT. But for a condition with limited treatment options and significant quality-of-life impact, the results are striking. Interstitial cystitis affects an estimated 3–8 million women in the United States, and current treatments (Elmiron, bladder instillations, physical therapy) offer incomplete relief for many patients.
Why Women's Guts Are Different
The female GI tract is biologically distinct from the male GI tract in ways that directly relate to BPC-157's mechanisms. Estrogen receptors line the gut epithelium and influence gut motility, permeability, and microbiome composition. When estrogen fluctuates (during menstrual cycles, pregnancy, and menopause), gut function changes with it.
This explains why IBS symptoms often worsen premenstrually, why new-onset digestive issues are common in perimenopause, and why women experience higher rates of functional GI disorders across their lifespan. The gut-hormone axis in women creates both vulnerability and opportunity — the vulnerability is clear; the opportunity is that peptides targeting gut repair may be particularly effective in the context of hormonal fluctuation.
How BPC-157 Works
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protein found in human gastric juice. Its mechanisms include promoting angiogenesis (new blood vessel formation), modulating the nitric oxide system, upregulating growth factor receptors, and reducing inflammatory signaling. The peptide has been described as a "cytoprotectant" — a substance that maintains and restores cell integrity across multiple organ systems.
For gut health specifically, BPC-157 promotes healing of the intestinal epithelial barrier, reduces inflammation in the gut wall, and supports restoration of normal gut motility. These effects have been documented across models of inflammatory bowel disease, leaky gut, gastric ulcers, and colitis.
Beyond the Gut: Recovery & Repair
BPC-157's tissue repair effects extend well beyond the GI tract. The knee pain study showed 11 of 12 patients receiving intra-articular BPC-157 achieved significant improvement. For women recovering from C-sections, hysterectomies, or other surgical procedures, BPC-157's wound healing and anti-inflammatory properties are directly relevant.
A 2025 systematic review screened 544 papers on BPC-157, with 36 meeting inclusion criteria. While 35 were animal studies, the consistency of results across multiple tissue types and injury models — combined with the emerging human data — positions BPC-157 as the most evidence-supported healing peptide available.
Where to Source BPC-157
Regulatory Status
BPC-157 was placed on the FDA's Category 2 restricted list in September 2023 and removed on April 22, 2026. It is scheduled for PCAC review at the July 23–24, 2026 meeting, where the committee will evaluate whether to add it to the 503A bulks list for legal compounding. Read our full regulatory explainer →